Dean Rudge

Dean Rudge

Deputy Editor

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest from Dean Rudge

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

Meitheal Adds To US Liraglutide List As It Looks To Ease Shortage Concerns

Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.

Glenmark Dodges UK Dapagliflozin Injunction Ahead Of Patent Trial Decision

A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition

Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.

What’s Next? Five Things To Look Out For In April

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

Kabi Lines Up Denosumab Biosimilar Launch As FDA Says Yes To Filings

Fresenius Kabi has met its end of the bargain to launch biosimilars to Prolia/Xgeva in the middle of this year, after bagging FDA approvals. The German firm is also set to hear back on its filings in Europe imminently.